AR051786A1 - Eif-5a especifico de la apoptosis y polinucleotidos que codifican el mismo - Google Patents

Eif-5a especifico de la apoptosis y polinucleotidos que codifican el mismo

Info

Publication number
AR051786A1
AR051786A1 ARP050105081A ARP050105081A AR051786A1 AR 051786 A1 AR051786 A1 AR 051786A1 AR P050105081 A ARP050105081 A AR P050105081A AR P050105081 A ARP050105081 A AR P050105081A AR 051786 A1 AR051786 A1 AR 051786A1
Authority
AR
Argentina
Prior art keywords
apoptosis
eif
specific
polinucleotides
coding
Prior art date
Application number
ARP050105081A
Other languages
English (en)
Inventor
John E Thompson
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of AR051786A1 publication Critical patent/AR051786A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

Factor de iniciacion eucarionte (eIF-5A) específico de apoptosis y uso de siARN que suprime la expresion endogena de eIF-5A específico de apoptosis en una célula y tiene la secuencia 3'-GCC UUA CUG AAG GUC GAC U-5'. Se una en un medicamento para tratar sepsis en mamíferos, inducir o aumentar la apoptosis en células cancerosas o disminuir la expresion de eIF-5A específico de apoptosis.
ARP050105081A 2004-12-03 2005-12-05 Eif-5a especifico de la apoptosis y polinucleotidos que codifican el mismo AR051786A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63251404P 2004-12-03 2004-12-03
US66662605P 2005-03-31 2005-03-31
US67588405P 2005-04-29 2005-04-29
US71139705P 2005-08-26 2005-08-26

Publications (1)

Publication Number Publication Date
AR051786A1 true AR051786A1 (es) 2007-02-07

Family

ID=36565863

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105081A AR051786A1 (es) 2004-12-03 2005-12-05 Eif-5a especifico de la apoptosis y polinucleotidos que codifican el mismo

Country Status (10)

Country Link
EP (2) EP1828383A2 (es)
JP (1) JP2008522591A (es)
KR (1) KR20070077225A (es)
AR (1) AR051786A1 (es)
AU (1) AU2005311586A1 (es)
CA (1) CA2588129A1 (es)
IL (1) IL183585A0 (es)
NZ (1) NZ556236A (es)
TW (1) TW200634154A (es)
WO (1) WO2006060823A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007226875A1 (en) * 2006-03-20 2007-09-27 Senesco Technologies, Inc. Use of eiF-5A1 siRNA and antisense to treat sepsis or haemorrhagic shock
CN102282259A (zh) * 2008-03-07 2011-12-14 森尼斯科技术公司 与有义构建体实现期望多核苷酸的表达的用途相组合的、sirna实现内源基因的减量调节的用途
WO2009144933A1 (ja) * 2008-05-27 2009-12-03 国立大学法人東京大学 アポトーシス誘導薬
WO2010028093A2 (en) * 2008-09-03 2010-03-11 Senesco Technologies, Inc. Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
JP5302054B2 (ja) * 2009-03-06 2013-10-02 オリンパス株式会社 Ｄｎａが断片化されたアポトーシス細胞の検出方法、細胞画像解析装置、及びプログラム
FR2962906A1 (fr) 2010-07-20 2012-01-27 Univ Nice Sophia Antipolis UTILISATION DES INHIBITEURS DE L'HYPUSINYLATION DE eIF5A POUR TRAITER LES PATHOLOGIES ISCHEMIQUES ET HYPOXIQUES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217517B2 (en) * 2001-07-23 2007-05-15 Senesco Technologies, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
US7968523B2 (en) * 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
NZ542665A (en) * 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
EP1636364A2 (en) * 2003-06-06 2006-03-22 Senesco Technologies, Inc. INHIBITION OF APOPTOSIS-SPECIFIC ELF-5A ( EIF-5A1) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS

Also Published As

Publication number Publication date
KR20070077225A (ko) 2007-07-25
EP1959010A3 (en) 2009-02-25
CA2588129A1 (en) 2006-06-08
TW200634154A (en) 2006-10-01
JP2008522591A (ja) 2008-07-03
EP1828383A2 (en) 2007-09-05
EP1959010A2 (en) 2008-08-20
WO2006060823A2 (en) 2006-06-08
NZ556236A (en) 2009-12-24
IL183585A0 (en) 2008-04-13
WO2006060823A3 (en) 2007-02-22
AU2005311586A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
SV2006002131A (es) Uso de un anticuerpo para el tratamiento de lupus
AR051786A1 (es) Eif-5a especifico de la apoptosis y polinucleotidos que codifican el mismo
CR8033A (es) Terapia de autoinmunidad a enfermedad en paciente con respuesta inadecuada al inhibidor tnf-alpha
ECSP055818A (es) Métodos y composiciones para inducir apoptosis en células de cáncer.
AR073717A1 (es) Anticuerpos anti-notch2 de murino y humano, y metodos de uso
PT1315520E (pt) Utilizacao de anticorpos trifuncionais biespecificos e triespecificos para tratamento de ascites malignas
ATE432986T1 (de) Menschlicher rezeptor für tumor necrosis factor
CL2008002085A1 (es) Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
AR053541A1 (es) Combinacion de xolair con agente inmunosupresor
ES2650463T3 (es) Tratamiento de enfermedades inflamatorias con ACE2
CR9518A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores
ES2187200T3 (es) Proteina hibrida para inhibir la desgranulacion de mastocitos y su uso.
PA8493401A1 (es) Uso de inhibidores de cyp2d6 en terapias de combinacion
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
SV2006002100A (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu
UY31724A (es) " compuestos heterocíclicos novedosos y usos de los mismos"
ATE281431T1 (de) Resorcin-derivate
AR044039A1 (es) Combinaciones antineoplasicas
ES2172680T3 (es) Ligante antagonista rar-gamma o agonista rar-alfa como inhibidor de apoptosis.
CL2012000392A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos para tratar cancer en combinacion con fludarabina .
UY28312A1 (es) Pirazolopirimidinas sustituidas con 6-ciclimetilo y 6-alquilmetilo
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
AR035079A1 (es) Uso de un inhibidor de la interaccion cd2/lfa-3
CR9853A (es) Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion
AR057234A1 (es) Uso de eif-5a para destruir celulas de meiloma multiple

Legal Events

Date Code Title Description
FB Suspension of granting procedure